MedTrace Logo

Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

NCT06705608 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2024-11-26

No results posted yet for this study

Summary

The goal of this retrospective observational study is to investigate the long-term safety of Fingolimod in individuals with Multiple Sclerosis (MS), specifically focusing on the risk of developing skin cancer. The main question it aims to answer is:

• Does the use of Fingolimod increase the incidence of skin cancer in individuals with MS compared to those using other disease-modifying therapies? Participants who are new users of Fingolimod or other active comparators as part of their regular medical care for MS will be included in this study. Researchers will use advanced causal inference techniques to analyze healthcare data and compare the incidence of skin cancer between these groups.

Conditions

  • Multiple Sclerosis
  • Skin Cancer
  • Skin Cancer Melanoma
  • Skin Cancers - Basal Cell Carcinoma
  • Skin Cancer, Squamous Cell
  • Multiple Sclerosis (MS) - Relapsing-remitting

Interventions

DRUG

Fingolimod

patients who received fingolimod for treating RRMS

DRUG

Natalizumab

patients who received natalizumab for treating RRMS (active comparator)

DRUG

Dimethyl fumarate (DMF)

patients who received dimethyl fumarate for treating RRMS (active comparator)

DRUG

Alemtuzumab

patients who received alemtuzumab for treating RRMS (active comparator)

DRUG

Teriflunomide

patients who received teriflunomide for treating RRMS (active comparator)

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-01
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06705608 on ClinicalTrials.gov